Cargando…

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure

Under continuous long-term treatment with abo- or onabotulinum toxin type A (BoNT/A), ~10 to 15% of patients with cervical dystonia (CD) will develop neutralizing antibodies and reduced responsiveness over an ~10-year treatment period. Among the botulinum neurotoxin type A preparations so far licens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hefter, Harald, Ürer, Beyza, Brauns, Raphaela, Rosenthal, Dietmar, Meuth, Sven G., Lee, John-Ih, Albrecht, Philipp, Samadzadeh, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779547/ https://www.ncbi.nlm.nih.gov/pubmed/35051021 http://dx.doi.org/10.3390/toxins14010044

Ejemplares similares

The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2022)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
por: Samadzadeh, Sara, et al.
Publicado: (2020)

No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity
por: Hefter, Harald, et al.
Publicado: (2023)

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
por: Hefter, Harald, et al.
Publicado: (2022)

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
por: Hefter, Harald, et al.
Publicado: (2020)

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
por: Samadzadeh, Sara, et al.
Publicado: (2020)

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany
por: Samadzadeh, Sara, et al.
Publicado: (2021)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
por: Hefter, Harald, et al.
Publicado: (2021)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
por: Hefter, Harald, et al.
Publicado: (2021)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
por: Hefter, Harald, et al.
Publicado: (2020)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
por: Hefter, Harald, et al.
Publicado: (2023)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report
por: Hefter, Harald, et al.
Publicado: (2021)

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis
por: Hefter, Harald, et al.
Publicado: (2013)

The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2020)

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2019)

Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease
por: Hefter, Harald, et al.
Publicado: (2022)

Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
por: Hefter, Harald, et al.
Publicado: (2023)

Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Incobotulinum Toxin A with a One-year Long-lasting Effect for Trapezius Contouring and Superior Efficacy for the Treatment of Trapezius Myalgia
por: Supornpun, Napamon, et al.
Publicado: (2022)

Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Analysis of Running in Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson’s Disease: A Controlled Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Cholinesterase Deficiency Syndrome—A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson’s Disease
por: Arslan, Max, et al.
Publicado: (2022)

Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)

Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients
por: Rostami, Rezvan, et al.
Publicado: (2016)

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
por: Hefter, Harald, et al.
Publicado: (2020)

Incobotulinum Toxin Type A for Treatment of Ultraviolet-B-Induced Hyperpigmentation: A Prospective, Randomized, Controlled Trial
por: Vachiramon, Vasanop, et al.
Publicado: (2022)

Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy
por: Jost, Wolfgang H., et al.
Publicado: (2012)

A Double-Blind, Split-Face, Randomized Study on the Effects and Safety of Intradermal Injection of Botulinum Toxin A (Incobotulinum Toxin A) in the Cheek
por: Shin, Dong Min, et al.
Publicado: (2022)

Long‐term adherence and response to botulinum toxin in different indications
por: Lee, John‐Ih, et al.
Publicado: (2020)

A Beautician's Dystonia: Long-Lasting Effect of Botulinum Toxin
por: Di Martino, Siria, et al.
Publicado: (2014)

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review
por: Hefter, Harald, et al.
Publicado: (2021)

The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication
por: Hefter, Harald, et al.
Publicado: (2022)

Botulinum toxin therapy of dystonia
por: Dressler, Dirk, et al.
Publicado: (2020)

Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson’s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review
por: Samadzadeh, Sara, et al.
Publicado: (2022)

An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport)
por: Hefter, H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_fnof16cru4d3u72omrt05kbm92